Analysis of Relevant Factors of Refractory and Relapse DLBCL Treated by Rituximab Combined with CHOP/EPOCH Regimen.
10.19746/j.cnki.issn.1009-2137.2020.06.020
- Author:
Jing ZHANG
1
;
Yan GU
1
;
Xue WU
1
;
Chong GAO
1
;
Bao-An CHEN
2
Author Information
1. Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, Jiangsu Province, China.
2. Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, Jiangsu Province, China,E-mail: cba8888@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Cyclophosphamide/therapeutic use*;
Doxorubicin/therapeutic use*;
Etoposide;
Humans;
Lymphoma, Large B-Cell, Diffuse/drug therapy*;
Neoplasm Recurrence, Local;
Prednisone/therapeutic use*;
Prognosis;
Retrospective Studies;
Rituximab/therapeutic use*;
Treatment Outcome;
Vincristine
- From:
Journal of Experimental Hematology
2020;28(6):1912-1918
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the efficacy of rituximab combined with CHOP/EPOCH regimen for treatment of diffuse large B-cell lymphoma（DLBCL） patients, and to explore the high risk factors of refractory and relapsed patients.
METHODS:The clinical data of 72 patients with de novo DLBCL from December 2012 to December 2018 in the Department of Hematology, Zhongda Hospital Affiliated to Southeast University were retrospectively analyzed. The remission rate of DLBCL patients treated by rituximab combined with CHOP/EPOCH was analyzed, and survival analysis was conducted to explore the risk factors influencing refractory recurrence.
RESULTS:45 cases among 72 patients achieved complete remission (CR), 11 cases achieved partial remission (PR), the total remission rate was 77.78%. 25 cases (34.2%) refractory and relapsed. Single factor analysis showed that the B symptoms, low Hb, high NLR, low MLR, high β
CONCLUSION:The remission rate of DLBCL patients treated by rituximab combined with CHOP/EPOCH regimen is high, but about one third of the patients still show refractory and relapsed. B Symptoms, anemia, high β
